Reishi (Ganoderma lucidum)

The VerdictLOW CONVICTION

Reishi is a well-tolerated mushroom with a real immune mechanism but no proven benefit for the sleep, stress, or immunity people buy it for.

Tonight, ask yourself why you're taking reishi. If it's for sleep or stress, stop. No completed human trial shows it works for either. If you keep it for general interest, at least buy a real fruiting-body extract, not cheap grain-grown mycelium that can be mostly starch.

The strongest human evidence is as a supervised add-on in cancer care, where it nudges immune markers but has not been shown to help people live longer. 2) The biggest consumer claim, reishi as the "calming mushroom" for sleep and stress, has zero completed human trials behind it. 3) If you take it, choose a β-glucan-standardised fruiting-body extract (~1.5-3 g/day with food), not cheap mycelium powder.

That's the general answer. Your stack is different.

Check your whole stack

Ask yourself why you're taking reishi. If it's for sleep or stress, stop. No completed human trial shows it works for either.

Reishi is a woody, bitter mushroom used in East Asian medicine for centuries. If you keep it for general interest, at least buy a real fruiting-body extract, not cheap grain-grown mycelium that can be mostly starch.

Takes less than 2 minutes. Check your bottle's label.

The Protocol

There is no established consumer dose for any endpoint. The numbers below are the ranges tested in human studies, not a guarantee of benefit.

Population	Dose	Timing / Form	Loading
General adult (immune interest)	~1.5-3 g/day extract	With food · β-glucan-standardised fruiting-body extract	No
Cancer supportive care	~1000 mg three times daily	With meals · clinician-supervised · standardised extract	No
Elevated triglycerides	Spore-oil trial dose (not standardised)	Per product · spore oil	No
Sleep / stress	Not established — no completed efficacy trial	—	—

Forms

Fruiting-body extract

Most trial evidence. Needs hot-water extraction to release β-glucans.

£10-20/mo

Grain-grown mycelium

Cheapest, but often high starch and low actual β-glucan.

£8-15/mo

Cracked spore powder

Cell wall must be cracked for any release.

£15-30/mo

Spore oil

The triglyceride trial used this concentrated fraction.

£20-40/mo

Absorption

β-glucans need hot-water or dual extraction to be released from the fungal cell wall, so a genuine extract beats raw powder. The decisive variable is how much actual β-glucan and triterpene the product contains, which is unregulated and varies enormously. No human study supports paying a premium for any one form on outcome grounds.

Safety & Interactions

Reishi is generally well tolerated short-term, but it has two real edges: a rare liver-injury signal, and additive effects with common medications, exactly the drugs the older "immunity" audience tends to be on.

Blood thinners (warfarin, aspirin, clopidogrel)

Triterpenes have antiplatelet activity. Additive bleeding risk, especially around surgery. Stop before any procedure and tell your prescriber.

Diabetes medication (insulin, sulfonylureas, metformin)

Possible additive glucose lowering in responders. Monitor blood sugar.

Blood-pressure medication

Possible additive blood-pressure lowering. Monitor.

Immunosuppressants (transplant / autoimmune)

β-glucan immune stimulation may work against the medication. Specialist sign-off only.

Contraindicated

Pregnancy and lactation: data unavailable, avoid.
Pre-surgical patients on anticoagulants/antiplatelets.
Transplant and autoimmune patients on immunosuppressants.
Liver disease: rare hepatotoxicity case literature warrants caution.

Side effects: dry mouth/throat, GI upset, occasionally dizziness or nosebleed at higher/longer doses. Rare liver-injury case reports (including one fatal fulminant hepatitis) are associated with powdered reishi. Upper limit: none established.

Conviction

LOW

The immune mechanism is real, but human outcomes are unproven for everything people buy reishi for. The blood-sugar claim is trending toward no effect after a 2024 trial found nothing, and the sleep/stress claim has no completed trial at all.

What would change this

For the consumer sleep claim: an independent, double-blind, placebo-controlled trial of at least 150 healthy adults with insomnia or elevated stress, using a β-glucan-standardised fruiting-body extract at a disclosed fixed dose for 8+ weeks, with a validated sleep or stress endpoint showing a clinically meaningful benefit, would move it from "unproven by absence" to LOW-MODERATE.

For cancer supportive care: a large (300+) independent trial with a hard endpoint (survival or a validated fatigue/quality-of-life scale) showing benefit would lift the adjunct conviction to MODERATE.

Worth Your Money?

Weekly cost~£2-5 per week at the tested extract range (about half a teaspoon of extract a day)

Worth it ifYou're using it as a clinician-supervised add-on in cancer supportive care.

Lower priority ifYou want better sleep or less stress. Your next £20 is better spent on a consistent wind-down routine and fixing sleep timing, both of which have far stronger evidence than reishi.

Skip (for consumer claims)

Go Deeper

Want to stop wasting money on supplements that don't work? The Verdict reviews one every week, free.

Get the free weekly review

Claims vs Evidence — See What the Research Found

What People Claim

"Reishi is the calming mushroom. Take it in the evening for deeper sleep and less stress. It boosts your immune system, supports your heart, and has been used for longevity for thousands of years."

These claims are not invented from nothing. Reishi has a genuine immune mechanism, a long traditional-use history as the "mushroom of immortality", and a real (if low-quality) human cancer-adjunct literature. The marketing leans on all three. The problem is the gap between where the evidence actually sits and what people buy reishi to do.

What the Evidence Actually Shows

Claim	Strength	What the data shows
Cancer supportive care (adjunct)	WEAK-MOD	~1.5× more likely to respond when added to chemo/radio; immune markers up; no survival benefit. Cochrane, low quality, not first-line.
Immune-cell biomarkers	WEAK	Marker shifts in small RCTs. Biomarker, not a clinical outcome.
Triglyceride reduction	EMERGING	One small 2025 spore-oil crossover. Promising, unreplicated.
Blood sugar / glycemic	DEBUNKED-leaning	2024 RCT (N=84, 16 wk) found no HbA1c or fasting-glucose effect; Cochrane "insufficient".
Cardiovascular risk	WEAK	Cochrane: insufficient evidence.
Sleep / stress ("calming")	NONE	No completed human efficacy trial. Ongoing studies only.
Cancer cure, longevity, anti-aging	NONE	Preclinical (rodent/in vitro) only.

What would change the sleep verdict: a completed, independent, placebo-controlled trial in healthy adults with a validated sleep endpoint. The ongoing WithPower (2025) and Mayo trials are the readouts to watch.

The Full Picture — Mechanism, Debate & Nuance

How It Works

Reishi carries two distinct active families, and the marketing blurs them. The first is its β-glucans, large branched sugars that immune cells genuinely recognise through specific receptors on macrophages, NK cells, and dendritic cells. This is the real basis for the immune-marker shifts. The mechanism is not fake. The open question is whether moving those markers changes outcomes people care about, and the human data do not yet show that it does.

The second family is the triterpenes, the ganoderic acids that give reishi its bitter taste and drive its anti-inflammatory, lipid-modulating, and liver-protective effects in lab models. In humans, that arm is limited to a single small spore-oil triglyceride trial and an inconclusive cardiovascular review.

The huge remainder of the reishi science, the antitumour, gut-microbiome, and anti-anxiety mechanism work, is preclinical: rodents, rabbits, zebrafish, and cell cultures. It supports hypotheses, not clinical efficacy. The only mechanistic thread under the "calming" claim is a mouse study.

The Debate

Does the cancer signal mean anything?

Cochrane review: reishi added to chemo/radiotherapy raised tumour-response rates and immune markers.

Same review: no survival benefit, evidence low-quality, explicitly not a first-line treatment.

A surrogate (response rate, immune markers) improves while the outcome that matters (survival) stays unproven. Classic biomarker-versus-outcome gap.

Does it help blood sugar?

Older small trials: hinted at metabolic benefit.

2024 RCT (N=84, 16 wk): no effect on HbA1c or fasting glucose.

A larger, better-controlled, longer trial nulls the early small-trial optimism. The field is trending toward "no effect."

Honest Limitations

Content variability

A label saying "reishi" can be grain-grown mycelium with little active compound. A consumer can take the marketed dose and ingest a fraction of what trials used, so real-world effect is likely weaker than even the modest lab signal.

Biomarker vs outcome

Lab studies measure immune markers and tumour-response rates. Consumers want sleep, calm, fewer colds, and longevity, none of which the human trials demonstrate.

Population mismatch

The best evidence is in cancer patients under specialist care. The buyers are healthy adults taking gummies for stress. The evidence does not transfer to the people purchasing it.

The Nuance

What doesn't work

Reishi for sleep and stress in healthy adults — the headline claim has no completed efficacy trial. It borrows its reputation from tradition and mouse data.
Reishi for blood sugar — a 2024 trial found no effect.
Reishi as a cancer treatment — the only positive human signal is as a low-certainty adjunct that improves response rates but not survival.
Premium-form superiority — no human study supports paying more for spore oil or cracked spores on outcome grounds.

Food-first note: there is no practical food version of reishi, it is too bitter and woody to eat. If your goal is calm or sleep, the cheapest high-evidence intervention is consistent sleep timing and a wind-down routine, not a mushroom extract.

Sources

Jin X, Ruiz Beguerie J, Sze DM, Chan GCF (2016). Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 5 RCTs ~373 patients. Adjunct raised response rate and immune markers; no survival benefit; low-quality. PMID 27045603.
Klupp NL, et al. (2015). Ganoderma lucidum mushroom for cardiovascular risk factors. Cochrane Database Syst Rev. 5 RCTs, 398 participants. Insufficient evidence. PMID 25686270.
Wu et al. (2024). Ganoderma lucidum in type 2 diabetes and metabolic syndrome. Sci Rep. RCT N=84, 16 wk; no HbA1c/FPG effect.
Spore-oil triglyceride trial (2025). Randomized, double-blind, crossover study; triglyceride reduction, small N. PMID 40077714.
Ganoderma lucidum dry extract modulates T lymphocyte function in older women (2024). RCT, biomarker endpoint. PMID 38800991.
Immune modulation by yogurt enriched with β-glucans from Ganoderma lucidum (2018). RCT. PMID 30317947.
Wachtel-Galor S, et al. (2004). Ganoderma lucidum ('Lingzhi'): acute and short-term biomarker response. RCT crossover; no adverse effects. PMID 14630595.
Efficacy and Toxicity of Ganoderma lucidum in Chemotherapy (2017, review). Hepatotoxicity discussion. PMID 29256841.